Biomark Diagnostics Inc. (CSE:BUX)

Market Cap	49.27M +42.4%
Revenue (ttm)	27.80K -82.1%
Net Income	-1.43M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Open	0.4900
Previous Close	0.4900
Day's Range	0.4900 - 0.5000
52-Week Range	0.2700 - 0.6400
Beta	-0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BUX

Financial Performance

In fiscal year 2026, Biomark Diagnostics's revenue was 59,787, a decrease of -61.23% compared to the previous year's 154,216. Losses were -1.48 million, -23.35% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error